About 5-hydroxytryptamine receptor 3D
5-hydroxytryptamine receptor 3D (HTR3D) is a protein
from Homo sapiens identified by UniProt accession
Q70Z44, 454 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 3D |
| UniProt accession | Q70Z44 |
| Gene | HTR3D |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (70)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.59
- post operative nausea and vomiting · score 0.57
- irritable bowel syndrome · score 0.54
- schizoaffective disorder · score 0.50
- type 2 diabetes mellitus · score 0.47
- Nausea and vomiting · score 0.46
- psychosis · score 0.46
- Chemotherapy-induced nausea and vomiting · score 0.44
- cancer · score 0.44
- Vomiting · score 0.43
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q70Z44-F1 | alphafold | PREDICTED | 63.38 | — |
Amino-acid sequence (454 residues)
MQKHSPGPPA LALLSQSLLT TGNGDTLIIN CPGFGQHRVD PAAFQAVFDR KAIGPVTNYS VATHVNISFT LSAIWNCYSR IHTFNCHHAR PWHNQFVQWN PDECGGIKKS GMATENLWLS DVFIEESVDQ TPAGLMASMS IVKATSNTIS QCGWSASANW TPSISPSMDR ARAWRRMSRS FQIHHRTSFR TRREWVLLGI QKRTIKVTVA TNQYEQAIFH VAIRRRCRPS PYVVNFLVPS GILIAIDALS FYLPLESGNC APFKMTVLLG YSVFLLMMND LLPATSTSSH ASLVAPLALM QTPLPAGVYF ALCLSLMVGS LLETIFITHL LHVATTQPLP LPRWLHSLLL HCTGQGRCCP TAPQKGNKGP GLTPTHLPGV KEPEVSAGQM PGPGEAELTG GSEWTRAQRE HEAQKQHSVE LWVQFSHAMD ALLFRLYLLF MASSIITVIC LWNT
Explore 5-hydroxytryptamine receptor 3D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets